Effect of carboxylesterase inhibition on the anti-tumour effects of irinotecan

Journal of International Medical Research

Volumn 33, Issue 1, 2005, Pages 84-89

  Morishita, Yukie ^a   Fujii, M ^a   Kasakura, Y ^a   Takayama, T ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bis p nitrophenylphosphate; Carboxylesterase; HT 29 xenograft mouse; Irinotecan (CPT 11); Pro drug

Indexed keywords

4 NITROPHENYL PHOSPHATE; CARBOXYLESTERASE; ENZYME INHIBITOR; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; ENZYME INHIBITION; GROWTH RATE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VOLUME;

EID: 13444254412     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000503300108     Document Type: Article

References (12)

1. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-854.
2. Hosokawa M, Watanabe N, Tsukada E, Fukumoto M, Ogasawara Y, Daimon M, et al: Multiplicity of carboxylesterase isozymes in mammals and humans: role in metabolic activation of prodrugs (in Japanese). Yakubutsudoutai 2001; 16: 92-93.
3. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000; 60: 1189-1192.
4. Hosokawa M, Maki T, Satoh T: Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Arch Biochem Biophys 1990; 227: 219-227.
5. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E: Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994; 17: 662-664.
6. Murphy SD, Cheever KL, Chow AYK, Brewster M: Organophosphate insecticide potentiation by carboxylesterase inhibitors. Proc Eur Soc Toxicol 1976; 17: 292-300.
7. Ahtee L, Auvinen H, Maenpau AR, Vaholo ML, Lehtinen M, Hulmekoski J: Comparison of central nervous system actions of taurine and N-pivaloyltourine. Acta Pharmacol Toxicol 1985; 57: 96-105.
8. Jansen WJM, Zwart B, Hulscher STM, Giaccone G, Pinedo HM, Boven E: CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997; 70: 335-340.
9. Boven E, Winograd B, Fodstad O, Lobbezoo MW, Pinedo HM: Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol 1998; 24: 567-573.
10. Guemei AA, Cottrell J, Bond R, Hehman H, Prudhomme M, Pavlov MV, et al: Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan. Cancer Chemother Pharmacol 2001; 47: 283-290.
11. Saitoh S, Sakata Y: Standard therapy of CPT-11 for colorectal cancer (in Japanese, English abstract). Gan To Kagaku Ryoho 2001; 28: 1345-1351.
12. Saltz LB, Cox IV, Blanke C, Rosen LS, Fehrenbacher L, Moore MI, et al: Irinotecon plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.